LANGUAGES
English
اردو
About Us
History
Company Profile
Vision, Mission & Values
Message From CEO
Board of Directors
Contact Us
Partnerships
Product Portfolio
Product List
Pharmaceuticals
Medical Technologies
Exports
Investors
Company Profile
Governance
Corporate Briefing Session
Notice of Corporate Briefing Session 2024
Corporate Briefing Session Presentation 2024
AGM 28-10-2024
Board of Directors
Shareholding Pattern
Name of Auditor & Legal Advisor
Video Message from CEO
Investor Relations
Online Form & Contact Person
Notices of General Meetings, Dividend / Bonus Declarations
Sitemap
Search
Media
Awards
Memberships
News & Updates
Website Last Updated
Election of Directors
Notice of Election of Directors
Detail of Submitted Proxies
Profile of Contesting Candidates
List of Shareholders
Proxy Form
Ballot Paper
Investor Information
PSX Symbol
Financial Ratios
Share Registrar
Free Float 30-09-2024
Code of Conduct
Shareholding Information
List of Non CNIC Shareholders
List of Unclaimed Dividends And Shares
Share Price
Financial Statements
Annual Reports
Interim Accounts
Financial Reports
Compliance Certificate
EHS Policy
Quality Policy
Patients
Disease Info
Drug Safety
Send Query
Physicians
CSR
Press & Media
Videos
Statement on Remdesivir
Statement on Lenacapavir
Select Therapeutic
ANALGESICS
Anti-Diabetic
Anti-histamines
Anti-Obesity
Anti-Ulcerant
ANTIBIOTICS
Antiinflammatory Analges
Antiviral
CARDIOLOGY
Central Nervous System
Dermatology
Diabetes
Expectorant
Gastroenterolog
Gastroenterology
GI Health/Infectious Disease
HEPATOLOGY
Infectious Disease
Musculoskeletal
Neurology
ONCOLOGY
UROLOGY
Select Bodyparts
Acute Coronary Syndrome
Allergies
Angina Pectoris
Anxiety
Bacterial Infections/Antibiotic
Benign Prostatic Hyperplasia (BPH)
Burns
Chemotherapy
Colorectal Cancer
Congestive Heart Failure
Cough
Diabetes
Dyslipidemia
Epilepsy
Erosive Esophagitis (EE) and Gastro-Esophageal Reflux Disease (GERD)
Functional Dyspepsia
Fungal Infections
GERD
GIT related Bacterial Infections and irritable bowel syndrome (IBS)
Hepatitis B
Hepatitis-C
Hypertension
Invasive Fungal infections/Antifungal
LIVER CIRRHOSIS
Male-pattern Baldness
Metabolic Syndrome
Muscle and Joint pain/Topical Analgesic
N/A
Neutropenia
NIDDM
Non opioid Analgesics (NSAIDs/COXIBs)
Peptic Ulcers
Respiratory tract infections.
A-Z
Z-A
Name:
Peg-INF
Company:
BF Biosciences Limited
Therapeutic Segment:
HEPATOLOGY
Area:
Hepatitis-C
Description:
Peg-INF (Pegylated Interferon Alpha 2a 180 mcg – 40KD) is available in vials containing 1 ml ready-to-inject solution. Peginterferon is part of a once-weekly regimen indicated in the treatment of chronic Hepatitis C in combination with Ribavirin.
TOP
English 
اردو 
